CORRECTED-UPDATE 2-U.S. approves Roche's Actemra arthritis drug
Corrects 5th graf to clarify Roche's Rituxan drug class
* U.S. FDA clears drug for use in rheumatoid arthritis
* Roche sees therapy as potential blockbuster (Adds background)
WASHINGTON, Jan 8 (Reuters) - The U.S. Food and Drug Administration has approved Roche Holding AG's (ROG.VX) Actemra to treat rheumatoid arthritis, the company said on Friday.
The drug, made by Roche's Genentech unit, is already approved for use in Europe and Japan and is expected by the company to become a blockbuster product.
The FDA approved the drug for treatment of adults with moderate to severe rheumatoid arthritis who do not respond well enough to another class of biotech drugs designed to block an inflammatory protein called tumor necrosis factor (TNF).
Actemra is an anti-interleukin-6 receptor antibody and works differently from TNF blockers such as Humira, sold by Abbott Laboratories (ABT.N), and Remicade, sold by Johnson & Johnson (JNJ.N).
Also known by its chemical name tocilizumab, Actemra will compete against Roche's own B-cell inhibitor therapy Rituxan and is seen by the company as a way to help diversify its business.
Actemra may be used alone or in combination with methotrexate or other disease modifying anti-rheumatic drugs.
Patients with rheumatoid arthritis experience inflamed membranes that line joints throughout the body, causing pain, stiffness and disability. The condition is estimated to affect more than 20 million people worldwide.
(Reporting by Susan Heavey and Deena Beasley; Editing Bernard Orr)
- White House reverses, says Obama met uncle and lived with him during law school
- Flights delayed as air pollution hits record in Shanghai
- South Africa mourns Mandela, will bury him on December 15 |
- Analysis: Boeing bidders dangle goodies to win 777X jetliner
- RPT-UPDATE 1-Ford leans on global Mustang to burnish overseas image